Population pharmacokinetics and pharmacodynamics of levofloxacin following intravenous infusion for respiratory tract infection

Yusuke Tanigawara, Takako Shimizu, Kyoichi Totsuka

Research output: Contribution to journalArticle

Abstract

Our population pharmacokinetic analysis of levofloxacin (LVFX) used 1,381 plasma drug concentration data from 64 healthy Japanese adult volunteers (including elderly and female subjects) and 195 subjects with respiratory tract infection administered intravenous infusions of 500 mg of LVFX once daily. Population pharmacokinetic parameters were estimated using a nonlinear mixed-effect model (NONMEM) applying a 2-compartment model as a pharmacokinetic structure model. Creatinine clearance was related to LVFX total body clearance, and body weight was related to distribution volume in the central and peripheral compartments. In plasma LVFX concentration simulation under using final estimates of population pharmacokinetic parameters, impaired renal function was associated with accumulated plasma concentration in repeated dosing of 500 mg once daily, but the application of a dose adjustment algorithm similar to that for oral LVFX prevented plasma concentration increase on days 1-7. Prediction of LVFX PK-PD parameters in the population with respiratory tract infection by Monte Carlo simulation showed that target AUC0-24h/MIC ≥ 30 considered necessary to eradicate Streptococcus pneumoniae and target C max/MIC ≥ 5 considered necessary to prevent the LVFX resistance were achieved in almost 100% at a dose of 500 mg once daily with MIC of 1 μg/mL or less. Oral LVFX bioavailability was estimated at 98% from population pharmacokinetic parameters for intravenous and oral administration. Systemic exposure to LVFX after intravenous administration resembles that after oral administration of the same dose. A dose of 500 mg once daily is thus appropriate in pharmacokinetics-pharmacodynamics.

Original languageEnglish
Pages (from-to)55-64
Number of pages10
JournalJapanese Journal of Chemotherapy
Volume59
Issue numberSUPPL. 1
Publication statusPublished - 2011 May

Fingerprint

Levofloxacin
Intravenous Infusions
Respiratory Tract Infections
Pharmacokinetics
Population
Intravenous Administration
Oral Administration
Streptococcus pneumoniae
Biological Availability
Volunteers
Creatinine
Body Weight
Kidney

Keywords

  • Levofloxacin
  • PK-PD
  • Population pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Population pharmacokinetics and pharmacodynamics of levofloxacin following intravenous infusion for respiratory tract infection. / Tanigawara, Yusuke; Shimizu, Takako; Totsuka, Kyoichi.

In: Japanese Journal of Chemotherapy, Vol. 59, No. SUPPL. 1, 05.2011, p. 55-64.

Research output: Contribution to journalArticle

@article{fe95fe4abbe84d3c86ce13319eb8b140,
title = "Population pharmacokinetics and pharmacodynamics of levofloxacin following intravenous infusion for respiratory tract infection",
abstract = "Our population pharmacokinetic analysis of levofloxacin (LVFX) used 1,381 plasma drug concentration data from 64 healthy Japanese adult volunteers (including elderly and female subjects) and 195 subjects with respiratory tract infection administered intravenous infusions of 500 mg of LVFX once daily. Population pharmacokinetic parameters were estimated using a nonlinear mixed-effect model (NONMEM) applying a 2-compartment model as a pharmacokinetic structure model. Creatinine clearance was related to LVFX total body clearance, and body weight was related to distribution volume in the central and peripheral compartments. In plasma LVFX concentration simulation under using final estimates of population pharmacokinetic parameters, impaired renal function was associated with accumulated plasma concentration in repeated dosing of 500 mg once daily, but the application of a dose adjustment algorithm similar to that for oral LVFX prevented plasma concentration increase on days 1-7. Prediction of LVFX PK-PD parameters in the population with respiratory tract infection by Monte Carlo simulation showed that target AUC0-24h/MIC ≥ 30 considered necessary to eradicate Streptococcus pneumoniae and target C max/MIC ≥ 5 considered necessary to prevent the LVFX resistance were achieved in almost 100{\%} at a dose of 500 mg once daily with MIC of 1 μg/mL or less. Oral LVFX bioavailability was estimated at 98{\%} from population pharmacokinetic parameters for intravenous and oral administration. Systemic exposure to LVFX after intravenous administration resembles that after oral administration of the same dose. A dose of 500 mg once daily is thus appropriate in pharmacokinetics-pharmacodynamics.",
keywords = "Levofloxacin, PK-PD, Population pharmacokinetics",
author = "Yusuke Tanigawara and Takako Shimizu and Kyoichi Totsuka",
year = "2011",
month = "5",
language = "English",
volume = "59",
pages = "55--64",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Population pharmacokinetics and pharmacodynamics of levofloxacin following intravenous infusion for respiratory tract infection

AU - Tanigawara, Yusuke

AU - Shimizu, Takako

AU - Totsuka, Kyoichi

PY - 2011/5

Y1 - 2011/5

N2 - Our population pharmacokinetic analysis of levofloxacin (LVFX) used 1,381 plasma drug concentration data from 64 healthy Japanese adult volunteers (including elderly and female subjects) and 195 subjects with respiratory tract infection administered intravenous infusions of 500 mg of LVFX once daily. Population pharmacokinetic parameters were estimated using a nonlinear mixed-effect model (NONMEM) applying a 2-compartment model as a pharmacokinetic structure model. Creatinine clearance was related to LVFX total body clearance, and body weight was related to distribution volume in the central and peripheral compartments. In plasma LVFX concentration simulation under using final estimates of population pharmacokinetic parameters, impaired renal function was associated with accumulated plasma concentration in repeated dosing of 500 mg once daily, but the application of a dose adjustment algorithm similar to that for oral LVFX prevented plasma concentration increase on days 1-7. Prediction of LVFX PK-PD parameters in the population with respiratory tract infection by Monte Carlo simulation showed that target AUC0-24h/MIC ≥ 30 considered necessary to eradicate Streptococcus pneumoniae and target C max/MIC ≥ 5 considered necessary to prevent the LVFX resistance were achieved in almost 100% at a dose of 500 mg once daily with MIC of 1 μg/mL or less. Oral LVFX bioavailability was estimated at 98% from population pharmacokinetic parameters for intravenous and oral administration. Systemic exposure to LVFX after intravenous administration resembles that after oral administration of the same dose. A dose of 500 mg once daily is thus appropriate in pharmacokinetics-pharmacodynamics.

AB - Our population pharmacokinetic analysis of levofloxacin (LVFX) used 1,381 plasma drug concentration data from 64 healthy Japanese adult volunteers (including elderly and female subjects) and 195 subjects with respiratory tract infection administered intravenous infusions of 500 mg of LVFX once daily. Population pharmacokinetic parameters were estimated using a nonlinear mixed-effect model (NONMEM) applying a 2-compartment model as a pharmacokinetic structure model. Creatinine clearance was related to LVFX total body clearance, and body weight was related to distribution volume in the central and peripheral compartments. In plasma LVFX concentration simulation under using final estimates of population pharmacokinetic parameters, impaired renal function was associated with accumulated plasma concentration in repeated dosing of 500 mg once daily, but the application of a dose adjustment algorithm similar to that for oral LVFX prevented plasma concentration increase on days 1-7. Prediction of LVFX PK-PD parameters in the population with respiratory tract infection by Monte Carlo simulation showed that target AUC0-24h/MIC ≥ 30 considered necessary to eradicate Streptococcus pneumoniae and target C max/MIC ≥ 5 considered necessary to prevent the LVFX resistance were achieved in almost 100% at a dose of 500 mg once daily with MIC of 1 μg/mL or less. Oral LVFX bioavailability was estimated at 98% from population pharmacokinetic parameters for intravenous and oral administration. Systemic exposure to LVFX after intravenous administration resembles that after oral administration of the same dose. A dose of 500 mg once daily is thus appropriate in pharmacokinetics-pharmacodynamics.

KW - Levofloxacin

KW - PK-PD

KW - Population pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=79959440616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959440616&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 55

EP - 64

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - SUPPL. 1

ER -